Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer

Sung Gwe Ahn, Jae Hoon Lee, Hak Woo Lee, Tae Joo Jeon, Young Hoon Ryu, Kun Min Kim, Joohyuk Sohn, Mijin Yun, Seung Ah Lee, Jeong Joon, Seung Il Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: We investigated the relationship between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) standardized uptake value (SUV) and 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Materials and methods: One hundred sixty-seven patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had RS. Maximum SUV was obtained from 18F-FDG-PET-CT; the cut-off point was 4. Results: The continuous RS and SUV correlated positively (Pearson's R = 0.555; P < 0.001). An inverse correlation was found between progesterone receptor (PR) expression by reverse transcriptase-polymerase chain reaction, and SUV (Pearson's R = -0.408; P < 0.001). Good agreement between dichotomized RS (<26 vs. ≥26) and SUV (<4 vs. ≥4) was observed in 137 of 167 patients (82.0%; 95% confidence interval [CI], 76.2-87.9). Among patients with low SUV, 114 of 115 (99.1% [95% CI, 97.4-100.0]) had tumors with lower RS (<26). Although 23 of 52 women (44.2% [95% CI, 30.7-57.7]) with high SUV had higher RS (≥26), all 13 women with high RS (≥31) had high-SUV tumors. Most cases with disagreements between SUV and RS (n = 30) were classified as high SUV/lower RS (n = 29). The discordant group had higher grade or elevated Ki67 expression (≥20%) compared with the low SUV/lower RS group (n = 109), but higher PR expression compared with the high SUV/higher RS group (n = 23). Multiple logistic regression analysis showed that high SUV were associated with higher RS (≥26). Conclusions: SUV, as a biologic parameter represented using a continuous variable, was found to associate with RS in ER-positive, HER2-negative breast cancer. Further studies may reveal the biology underlying the discordance between the markers.

Original languageEnglish
Article numbere0175048
JournalPLoS One
Volume12
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Fluorodeoxyglucose F18
Estrogen Receptors
breast neoplasms
confidence interval
Genes
Breast Neoplasms
Recurrence
Progesterone Receptors
positron-emission tomography
Tumors
neoplasms
genes
computed tomography
Positron emission tomography
Polymerase chain reaction
RNA-Directed DNA Polymerase
regression analysis
reverse transcriptase polymerase chain reaction
Regression analysis
Tomography

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ahn, Sung Gwe ; Lee, Jae Hoon ; Lee, Hak Woo ; Jeon, Tae Joo ; Ryu, Young Hoon ; Kim, Kun Min ; Sohn, Joohyuk ; Yun, Mijin ; Lee, Seung Ah ; Joon, Jeong ; Kim, Seung Il. / Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. In: PLoS One. 2017 ; Vol. 12, No. 4.
@article{115cdc75e9c34aceb42085e877b8e6a6,
title = "Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer",
abstract = "Background: We investigated the relationship between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) standardized uptake value (SUV) and 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Materials and methods: One hundred sixty-seven patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had RS. Maximum SUV was obtained from 18F-FDG-PET-CT; the cut-off point was 4. Results: The continuous RS and SUV correlated positively (Pearson's R = 0.555; P < 0.001). An inverse correlation was found between progesterone receptor (PR) expression by reverse transcriptase-polymerase chain reaction, and SUV (Pearson's R = -0.408; P < 0.001). Good agreement between dichotomized RS (<26 vs. ≥26) and SUV (<4 vs. ≥4) was observed in 137 of 167 patients (82.0{\%}; 95{\%} confidence interval [CI], 76.2-87.9). Among patients with low SUV, 114 of 115 (99.1{\%} [95{\%} CI, 97.4-100.0]) had tumors with lower RS (<26). Although 23 of 52 women (44.2{\%} [95{\%} CI, 30.7-57.7]) with high SUV had higher RS (≥26), all 13 women with high RS (≥31) had high-SUV tumors. Most cases with disagreements between SUV and RS (n = 30) were classified as high SUV/lower RS (n = 29). The discordant group had higher grade or elevated Ki67 expression (≥20{\%}) compared with the low SUV/lower RS group (n = 109), but higher PR expression compared with the high SUV/higher RS group (n = 23). Multiple logistic regression analysis showed that high SUV were associated with higher RS (≥26). Conclusions: SUV, as a biologic parameter represented using a continuous variable, was found to associate with RS in ER-positive, HER2-negative breast cancer. Further studies may reveal the biology underlying the discordance between the markers.",
author = "Ahn, {Sung Gwe} and Lee, {Jae Hoon} and Lee, {Hak Woo} and Jeon, {Tae Joo} and Ryu, {Young Hoon} and Kim, {Kun Min} and Joohyuk Sohn and Mijin Yun and Lee, {Seung Ah} and Jeong Joon and Kim, {Seung Il}",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0175048",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. / Ahn, Sung Gwe; Lee, Jae Hoon; Lee, Hak Woo; Jeon, Tae Joo; Ryu, Young Hoon; Kim, Kun Min; Sohn, Joohyuk; Yun, Mijin; Lee, Seung Ah; Joon, Jeong; Kim, Seung Il.

In: PLoS One, Vol. 12, No. 4, e0175048, 01.04.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer

AU - Ahn, Sung Gwe

AU - Lee, Jae Hoon

AU - Lee, Hak Woo

AU - Jeon, Tae Joo

AU - Ryu, Young Hoon

AU - Kim, Kun Min

AU - Sohn, Joohyuk

AU - Yun, Mijin

AU - Lee, Seung Ah

AU - Joon, Jeong

AU - Kim, Seung Il

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background: We investigated the relationship between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) standardized uptake value (SUV) and 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Materials and methods: One hundred sixty-seven patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had RS. Maximum SUV was obtained from 18F-FDG-PET-CT; the cut-off point was 4. Results: The continuous RS and SUV correlated positively (Pearson's R = 0.555; P < 0.001). An inverse correlation was found between progesterone receptor (PR) expression by reverse transcriptase-polymerase chain reaction, and SUV (Pearson's R = -0.408; P < 0.001). Good agreement between dichotomized RS (<26 vs. ≥26) and SUV (<4 vs. ≥4) was observed in 137 of 167 patients (82.0%; 95% confidence interval [CI], 76.2-87.9). Among patients with low SUV, 114 of 115 (99.1% [95% CI, 97.4-100.0]) had tumors with lower RS (<26). Although 23 of 52 women (44.2% [95% CI, 30.7-57.7]) with high SUV had higher RS (≥26), all 13 women with high RS (≥31) had high-SUV tumors. Most cases with disagreements between SUV and RS (n = 30) were classified as high SUV/lower RS (n = 29). The discordant group had higher grade or elevated Ki67 expression (≥20%) compared with the low SUV/lower RS group (n = 109), but higher PR expression compared with the high SUV/higher RS group (n = 23). Multiple logistic regression analysis showed that high SUV were associated with higher RS (≥26). Conclusions: SUV, as a biologic parameter represented using a continuous variable, was found to associate with RS in ER-positive, HER2-negative breast cancer. Further studies may reveal the biology underlying the discordance between the markers.

AB - Background: We investigated the relationship between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) standardized uptake value (SUV) and 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Materials and methods: One hundred sixty-seven patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had RS. Maximum SUV was obtained from 18F-FDG-PET-CT; the cut-off point was 4. Results: The continuous RS and SUV correlated positively (Pearson's R = 0.555; P < 0.001). An inverse correlation was found between progesterone receptor (PR) expression by reverse transcriptase-polymerase chain reaction, and SUV (Pearson's R = -0.408; P < 0.001). Good agreement between dichotomized RS (<26 vs. ≥26) and SUV (<4 vs. ≥4) was observed in 137 of 167 patients (82.0%; 95% confidence interval [CI], 76.2-87.9). Among patients with low SUV, 114 of 115 (99.1% [95% CI, 97.4-100.0]) had tumors with lower RS (<26). Although 23 of 52 women (44.2% [95% CI, 30.7-57.7]) with high SUV had higher RS (≥26), all 13 women with high RS (≥31) had high-SUV tumors. Most cases with disagreements between SUV and RS (n = 30) were classified as high SUV/lower RS (n = 29). The discordant group had higher grade or elevated Ki67 expression (≥20%) compared with the low SUV/lower RS group (n = 109), but higher PR expression compared with the high SUV/higher RS group (n = 23). Multiple logistic regression analysis showed that high SUV were associated with higher RS (≥26). Conclusions: SUV, as a biologic parameter represented using a continuous variable, was found to associate with RS in ER-positive, HER2-negative breast cancer. Further studies may reveal the biology underlying the discordance between the markers.

UR - http://www.scopus.com/inward/record.url?scp=85017590332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017590332&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0175048

DO - 10.1371/journal.pone.0175048

M3 - Article

C2 - 28419166

AN - SCOPUS:85017590332

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0175048

ER -